In order to strengthen its oncology portfolio, Gilead Sciences has entered into a research collaboration, option and license agreement with Merus to discover novel dual tumour-associated antigens (TAA)-targeting trispecific antibodies. The collaboration, that could be worth up to US$1.58 B, will leverage Merus’ proprietary Triclonics® platform along with Gilead’s oncology expertise to develop preclinical research programmes. This deal could represent a significant stride towards innovative therapies and underscores the immense potential of TAA-targeting trispecific antibodies to advance the treatment of cancer.